SCHEMBL2570586

SCHEMBL2570586

CC(C)(C)c1nc(-c2cccc(O)c2)cn1CC1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.39
HSD17B1 P14061 2/20 0.38
HSD17B2 P37059 2/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
OPRD1 P41143 3/20 0.37
OPRK1 P41145 3/20 0.37
OPRM1 P35372 2/20 0.37
PDE4D Q08499 2/20 0.36
PDE7A Q13946 1/20 0.36
BRD4 O60885 2/20 0.36
PIK3CA P42336 3/20 0.36
PIK3R1 P27986 2/20 0.36
MLLT3 P42568 1/20 0.35
MLLT1 Q03111 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2568565 0.87 TLR8 (0.42) CNR2RAB9ANPC1PDE4DBRD4
SCHEMBL2574758 0.87 CNR2 (0.40) CNR2RAB9ANPC1BRD4PIK3CA
SCHEMBL2574935 0.86 CNR2 (0.39) CNR2RAB9ANPC1PDE4DBRD4
SCHEMBL2572325 0.86 KDM4C (0.47) CNR2PDE4DPDE7ABRD4
SCHEMBL2572164 0.84 ADORA2A (0.47) RAB9ANPC1MEN1MAPTKMT2A
SCHEMBL2570763 0.84 CNR2 (0.43) CNR2
SCHEMBL2571643 0.82 KEAP1 (0.48) CNR2RAB9ANPC1MEN1MAPT
SCHEMBL2570136 0.81 BRD4 (0.45) CNR2OPRD1OPRK1OPRM1BRD4
SCHEMBL2572531 0.81 BMP1 (0.46) BRD4PIK3CAMEN1MAPTKMT2A
SCHEMBL2573286 0.81 MEN1 (0.44) CNR2PDE4DBRD4HDAC6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289502-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-15 US disclosed
US-8273738-B2 Imidazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-09-25 US disclosed
EP-2090570-B1 IMIDAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2011-11-09 EP disclosed
US-20100152178-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
EP-2090570-A1 IMIDAZOLE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289502-A1 IMIDAZOLE DERIVATIVES CNR1, CNR2, ARRB1 CNR2 2/4885HSD17B1 1726/4885HSD17B2 1381/4885
US-20100152178-A1 IMIDAZOLE DERIVATIVES CNR1, CNR2, ARRB1 CNR2 2/4885HSD17B1 1726/4885HSD17B2 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.